Dicerna Pharma (DRNA) Tops Q3 EPS by 24c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall St rises as AI momentum holds heading into key earnings, Fed decision
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- S&P Global explores potential separation of Capital IQ business
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- Equities end higher as Anthropic's IPO filing buoys AI stocks
Dicerna Announces Third Quarter 2021 Financial Results and Provides a Business Update
November 9, 2021 7:30 AM ESTReported Positive Top-Line Data From Pivotal PHYOX2 Clinical Trial of Nedosiran Investigational GalXC RNAi Therapy for Treatment of Primary Hyperoxaluria (PH)
Initiated Phase 1 Clinical Trial of DCR-AUD for the Treatment of Alcohol Use Disorder (AUD)
Company Plans to Unveil First GalXC-Plus Extrahepatic Target in Early 2022
Cash Runway Extends Into 2025
Company to Host Conference Call Today at 8:30 a.m. ET
LEXINGTON, Mass.--(BUSINESS... More



